Why the Food Allergy Market Has Big Pharma Going Nuts Again

Food allergies are no longer considered a niche healthcare challenge. Across the world, rising diagnosis rates, increasing patient awareness, and growing concerns around severe allergic reactions are placing food allergy management higher on the healthcare and pharmaceutical agenda.

During recent years—and especially over the past several months—the industry has seen renewed momentum in the development of therapies targeting food allergies, particularly treatments focused on immunoglobulin E (IgE), a key antibody involved in allergic responses.

This renewed focus reflects the scale of the unmet need. In the United States alone, more than 32 million people are estimated to live with at least one food allergy, including millions of children. For many patients and families, daily life involves constant vigilance, dietary restrictions, and the ongoing risk of severe allergic reactions.

Historically, treatment options have been limited. Management has relied heavily on allergen avoidance and emergency interventions, while many early therapeutic approaches faced challenges around long-term adoption, treatment burden, and accessibility.

Recent industry investments further highlight how strategically important this space is becoming. In early 2026, GSK announced a $2.2 billion acquisition of Rapt Therapeutics to strengthen its immunology and inflammation pipeline through access to a next-generation anti-IgE monoclonal antibody designed for food allergy protection. Around the same period, Novartis acquired early-stage biotech Excellergy in a deal worth up to $2 billion, reinforcing growing pharmaceutical interest in advanced allergy therapies and next-generation IgE-targeting approaches. These investments reflect increasing confidence that food allergy treatment could become one of the most important emerging areas within immunology and biologic innovation.

This shift also reflects a broader transformation in modern healthcare: moving beyond symptom management toward more preventative, personalized, and long-term approaches to chronic conditions.

At the same time, the growing attention around food allergies is contributing to wider conversations about healthcare accessibility, pediatric care, quality of life, and the importance of innovation in immunology and inflammatory disease management.

Food Allergy Awareness Week serves as an important reminder that food allergies are not simply dietary inconveniences—they are serious medical conditions that affect millions of individuals, families, schools, workplaces, and healthcare systems worldwide.

As research continues to advance, collaboration between healthcare providers, researchers, patient advocacy groups, and the pharmaceutical industry will remain essential in improving outcomes and expanding access to effective therapies.

Follow PharmaXcelerate for more insights on healthcare innovation, biopharma and the future of patient-centered care.